|
|
 |
 |
| A common problem in companion animals |
|
Based on a survey conducted in 2005 among 109 U.S. veterinarians, chronic kidney disease affects, on average, 10.8% of cats and 5.2% of dogs brought in for consultation.1
|
 |
The term “renal failure” refers to persistent azotemia accompanied by an inability to concentrate urine, usually resulting from a 75% loss of nephron function in both kidneys. |
|
Kidney disease is a leading cause of death in dogs and cats.2 |
|
|
| An insidious process: The downward spiral of renal failure |
|
Azotemia is defined as an increased concentration of nonprotein nitrogenous compounds – usually urea and creatinine – in the blood, resulting from the kidneys’ impaired ability to fiter and eliminate waste. |
|
Current medical management of renal failure consists of supportive and symptomatic therapy designed to address underlying conditions (if known). |
|
Except for dialysis and kidney transplants, which are not common in veterinary medicine, nothing has been available to specifically focus on the reduction of toxin buildup in the blood… until now. |
 |
| New hope for compromised kidneys through targeted use of beneficial bacteria Introducing Azodyl… |
|
Breakthrough bacterial product for the reduction of azotemia in dogs and cats. |
|
Patented formulation of naturally-occurring beneficial bacteria (Kibow Biotics®) that metabolize and flush out uremic toxins that have diffused into the bowel. |
|
Supports kidney function by providing natural Enteric Dialysis®. Slows down uremic toxin buildup in the blood and helps prevent further kidney damage. |
|
Minimizes the clinical and biochemical consequences of reduced renal function. |
|
The product of choice at the first signs of azotemia in cases of acute or chronic kidney disease. |
 |
A powerful combination for advanced
renal support |
|
Azodyl is the first veterinary product to specifically focus on the reduction of azotemia.
• Ideally suited for use in IRIS stages II to IV. |
|
While Epakitin™ has been shown to contribute to lower urea concentrations, its strength lies in its ability to reduce serum phosphorous levels. |
|
Used together, Azodyl and Epakitin help reduce azotemia and phosphatemia.
• Minimizing consequences of renal failure
• Improving prognosis
• Enhancing quality of life |
|
Azodyl can safely be used with other conventional renal failure treatments, according to symptoms. |
|
|
| Promising results: Azodyl reduces azotemia in minipigs1 |
 |
|
Conclusion: Azodyl administered orally on a daily basis has the potential to decrease BUN levels and prolong survival in renal insuficiency.
|
|
Study involved six 5/6th nephrectomized (equivalent to approximately 85% loss of kidney function) minipigs with moderate azotemia (mean = 104.2 ± 40.0 mg/dL), four weeks post-nephrectomy. 2-4 weeks after the beginning of the study:
- Placebo group = significant increase (p = 0.009) in mean BUN (to 150 ± 0 mg/dL) when compared to the Azodyl group
- Azodyl group = decrease in BUN (to 75.1 ± 37.9 mg/dL) 8 weeks after the beginning of the study:
- Placebo group = all minipigs died
- Azodyl group = significant decrease (p=0.0016) in BUN (to 45.0 ± 5.0 mg/dL)
|
| Promising results: Preliminary clinical evaluation of Azodyl on feline azotemia2 |
 |
|
Conclusion: Azodyl administered orally on a daily basis has the potential to decrease BUN and creatinine levels, and has a place in the management of chronic kidney disease in cats.
|
|
Study involved seven cats presented to the author’s clinic with elevated BUN (41 to 74 mg/dL) and serum creatinine (2.6 to 7.9 mg/dL). All cats received Azodyl for a period of 60 days. Results at Day 60 indicate a decrease in BUN in all cats and a reduction in creatinine levels in six out of seven (86%) patients treated with Azodyl, even though dosing was less than the recommended amount in most cats. Reductions in serum BUN and creatinine levels were also observed at Day 30.
|
Read more about Azodyl™ in our brochure
|
|
|
|
